Cargando…
Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery withi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978773/ https://www.ncbi.nlm.nih.gov/pubmed/32010004 http://dx.doi.org/10.3389/fpsyg.2019.02741 |
_version_ | 1783490769657528320 |
---|---|
author | Parker, Sophie Kate Mulligan, Lee D. Milner, Philip Bowe, Samantha Palmier-Claus, Jasper E. |
author_facet | Parker, Sophie Kate Mulligan, Lee D. Milner, Philip Bowe, Samantha Palmier-Claus, Jasper E. |
author_sort | Parker, Sophie Kate |
collection | PubMed |
description | Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery within the NHS. Treatments which partial out potential active ingredients and are aimed at a range of psychological difficulties seen within this population have the potential to be more efficacious and efficient. We conducted a single-arm exploratory pilot trial, designed to investigate the feasibility and acceptability of Metacognitive therapy for individuals at ultra-high risk (UHR) of developing psychosis. Trial uptake was good, with 11 out of 12 referred individuals meeting for an eligibility assessment (one individual was excluded prior to the assessment). Of these, 10 individuals were eligible and included in the trial. Retention to treatment was high with 80% treatment adherence gained and an overall average of 8 sessions completed. All participants were offered follow-up assessments immediately post-treatment and at 6 months, which comprised measures of psychotic like experiences, anxiety and depression, and metacognitive processes implicated in the model. Retention to the post-treatment (12-week) follow-up was good, with 80% completion; however retention to the 6-month follow-up was lower at 60%. Clinically significant results were observed in psychotic like experiences, anxiety, depression and functioning with medium to large effect sizes. Measures related to beliefs and processes targeted within MCT showed clinically significant change with medium to large effect sizes. Our results suggest that MCT based upon a specific metacognitive model for individuals meeting ARMS criteria may be an important treatment target and warrants further attention. Limitations and possible focuses for future research are discussed. Registration: ISRCTN53190465 http://www.isrctn.com/ISRCTN53190465. |
format | Online Article Text |
id | pubmed-6978773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69787732020-02-01 Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study Parker, Sophie Kate Mulligan, Lee D. Milner, Philip Bowe, Samantha Palmier-Claus, Jasper E. Front Psychol Psychology Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery within the NHS. Treatments which partial out potential active ingredients and are aimed at a range of psychological difficulties seen within this population have the potential to be more efficacious and efficient. We conducted a single-arm exploratory pilot trial, designed to investigate the feasibility and acceptability of Metacognitive therapy for individuals at ultra-high risk (UHR) of developing psychosis. Trial uptake was good, with 11 out of 12 referred individuals meeting for an eligibility assessment (one individual was excluded prior to the assessment). Of these, 10 individuals were eligible and included in the trial. Retention to treatment was high with 80% treatment adherence gained and an overall average of 8 sessions completed. All participants were offered follow-up assessments immediately post-treatment and at 6 months, which comprised measures of psychotic like experiences, anxiety and depression, and metacognitive processes implicated in the model. Retention to the post-treatment (12-week) follow-up was good, with 80% completion; however retention to the 6-month follow-up was lower at 60%. Clinically significant results were observed in psychotic like experiences, anxiety, depression and functioning with medium to large effect sizes. Measures related to beliefs and processes targeted within MCT showed clinically significant change with medium to large effect sizes. Our results suggest that MCT based upon a specific metacognitive model for individuals meeting ARMS criteria may be an important treatment target and warrants further attention. Limitations and possible focuses for future research are discussed. Registration: ISRCTN53190465 http://www.isrctn.com/ISRCTN53190465. Frontiers Media S.A. 2020-01-17 /pmc/articles/PMC6978773/ /pubmed/32010004 http://dx.doi.org/10.3389/fpsyg.2019.02741 Text en Copyright © 2020 Parker, Mulligan, Milner, Bowe and Palmier-Claus. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychology Parker, Sophie Kate Mulligan, Lee D. Milner, Philip Bowe, Samantha Palmier-Claus, Jasper E. Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study |
title | Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study |
title_full | Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study |
title_fullStr | Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study |
title_full_unstemmed | Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study |
title_short | Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study |
title_sort | metacognitive therapy for individuals at high risk of developing psychosis: a pilot study |
topic | Psychology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978773/ https://www.ncbi.nlm.nih.gov/pubmed/32010004 http://dx.doi.org/10.3389/fpsyg.2019.02741 |
work_keys_str_mv | AT parkersophiekate metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy AT mulliganleed metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy AT milnerphilip metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy AT bowesamantha metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy AT palmierclausjaspere metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy |